The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 7 of the 49 sources its claims cite were checked for support.
Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency
Open accessAbstract
CONTEXT: P450 oxidoreductase deficiency (PORD) is a unique congenital adrenal hyperplasia variant that manifests with glucocorticoid deficiency, disordered sex development (DSD), and skeletal malformations. No comprehensive data on genotype-phenotype correlations in Caucasian patients are available. OBJECTIVE: The objective of the study was to establish genotype-phenotype correlations in a large PORD cohort. DESIGN: The design of the study was the clinical, biochemical, and genetic assessment including multiplex ligation-dependent probe amplification (MLPA) in 30 PORD patients from 11 countries. RESULTS: We identified 23 P450 oxidoreductase (POR) mutations (14 novel) including an exonic deletion and a partial duplication detected by MLPA. Only 22% of unrelated patients carried homozygous POR mutations. p.A287P was the most common mutation (43% of unrelated alleles); no other hot spot was identified. Urinary steroid profiling showed characteristic PORD metabolomes with variable impairment of 17α-hydroxylase and 21-hydroxylase. Short cosyntropin testing revealed adrenal insufficiency in 89%. DSD was present in 15 of 18 46,XX and seven of 12 46,XY individuals. Homozygosity for p.A287P was invariably associated with 46,XX DSD but normal genitalia in 46,XY individuals. The majority of patients with mild to moderate skeletal malformations, assessed by a novel scoring system, were compound heterozygous for missense mutations, whereas nearly all patients with severe malformations carried a major loss-of-function defect on one of the affected alleles. CONCLUSIONS: We report clinical, biochemical, and genetic findings in a large PORD cohort and show that MLPA is a useful addition to POR mutation analysis. Homozygosity for the most frequent mutation in Caucasians, p.A287P, allows for prediction of genital phenotype and moderate malformations. Adrenal insufficiency is frequent, easily overlooked, but readily detected by cosyntropin testing.
Overview
CoChat Summary
TL;DR
This study reports clinical, biochemical, and genetic findings in 30 patients with P450 oxidoreductase deficiency (PORD) from 11 countries, identifying 23 POR mutations including 14 novel ones. It establishes genotype-phenotype correlations, notably that homozygous p.A287P predicts 46,XX DSD and normal male genitalia, while severe skeletal malformations are associated with a major loss-of-function allele.
Key findings
- Among 54 unrelated alleles, p.A287P was the most common mutation, present on 23 alleles (43%); only 22% of unrelated patients carried homozygous POR mutations.
- Adrenal insufficiency was detected by short cosyntropin testing in 24 of 27 patients (89%); 13 received permanent hydrocortisone replacement and 11 received stress-dose cover.
- DSD occurred in 15 of 18 46,XX patients (83%) and 7 of 12 46,XY patients (58%). All four 46,XX individuals homozygous for p.A287P had 46,XX DSD, whereas both 46,XY p.A287P homozygotes had normal male external genitalia.
- Patients with severe malformations (total malformation score 9–16) were all compound heterozygous with a null mutation on one allele; p.A287P homozygotes had mild to moderate malformations with scores between 4 and 8.
Methods
- Clinical, biochemical, and genetic assessment was performed in 30 PORD patients (27 unrelated) from 11 countries, mostly Caucasian.
- POR mutation analysis used direct sequencing of coding exons and exon-intron boundaries plus multiplex ligation-dependent probe amplification (MLPA); novel missense mutants were functionally tested in a microsomal yeast coexpression assay, and novel splice-site mutations were analyzed in silico.
- Urinary steroid profiling by GC/MS measured substrate-to-product ratios reflecting 17α-hydroxylase and 21-hydroxylase activity, and a novel six-domain PORD malformation score (range 0–16) was used to grade skeletal severity.
Limitations
- The paper states that despite MLPA, no POR mutation was detected on 11% of unrelated alleles, and no correlation was found between POR genotype and the presence or severity of glucocorticoid deficiency.
- The paper notes that mild malformations may be overlooked and that long-term follow-up of well-characterized patients is needed to reveal the full impact of mutant POR.
- Evident from the text: the cohort is small (n = 30) and ethnically mixed but mostly Caucasian, limiting generalizability; functional testing was performed only for selected novel missense mutants, while splice-site effects relied on in silico prediction.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
6 Valid · 0 Not valid · 24 Not checked · 81 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“No PORD patient carrying null mutations on both alleles has been described so far, suggesting incompatibility of such genotype with postnatal life, similar to the observation of early fetal death in the murine por deletion model (19, 20).”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Abstract > Conclusions:
What the sources say
- Partly supportedcites [19] Shen AL O'Leary KA Kasper CB 2002 Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277: 6536– 6541 11742006 sourceExperimental — accuracy not yet measured
The Results report that homozygous CYPOR-null mice were absent among 2-week-old offspring and that no homozygous embryos were observed after E13.5. This supports prenatal lethality in the mouse deletion model, but the paper does not establish that people with PORD carrying null mutations on both alleles cannot survive postnatally. (LLM, conf=0.86)
- Supportedcites [20] Otto DM Henderson CJ Carrie D Davey M Gundersen TE Blomhoff R Adams RH Tickle C Wolf CR 2003 Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 23: 6103– 6116 12917333 PMC180925 source
The citation supports the murine comparison in the citing sentence, not the separate statement that no PORD patient with two null alleles has been described. The Results section (‘Generation of Cpr−/− mice’) reports no Cpr−/− pups and no viable mutant embryos at 10.5 days postcoitum, confirming early embryonic death in the mouse deletion model. (LLM, conf=0.93)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vivo impairment, particularly of CYP3A4, has recently been demonstrated in a patient with PORD (12), which has important implications for steroid replacement and drug therapy in affected patients.”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Abstract > Conclusions:
What the sources say
- Supportedcites [12] Tomalik-Scharte D Maiter D Kirchheiner J Ivison HE Fuhr U Arlt W 2010 Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 163: 919– 924 20844025 PMC2977993 source
The Discussion reports that in vivo CYP3A4 activity was grossly reduced in the patient with POR deficiency. It also identifies implications for steroid replacement and drug therapy. (LLM, conf=0.94)
boostedstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, in vitro activity of microsomal CYP enzymes involved in drug metabolism can be impaired by mutant POR (11).”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Abstract > Conclusions:
What the sources say
- Supportedcites [11] Miller WL Agrawal V Sandee D Tee MK Huang N Choi JH Morrissey K Giacomini KM 2011 Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 336: 174– 179 21070833 PMC4632974 source
The “POR and drug metabolism” section reports in vitro CYP3A4 assays in which the POR mutants A287P and R457H supported little or minimal metabolism of several drugs. It also reports reduced CYP2D6 activity with the A503V variant. These findings support the claim that mutant POR can impair drug-metabolizing microsomal CYP activity. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although the data in our study were based on 24-h urine collections, similar information can be obtained from a GC/MS analysis of spot urines (25).”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Discussion
What the sources say
- Supportedcites [25] Krone N Hughes BA Lavery GG Stewart PM Arlt W Shackleton CH 2010 Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol 121: 496– 504 20417277 PMC2941839 source
The “Quantitative data” section says most steroid disorders can be identified from spot or random urine samples, supporting the claim that spot-urine GC/MS can provide similar diagnostic information. It also qualifies that accurate 24-hour sampling is needed for quantitative excretion data and certain evaluations, such as aldosterone synthesis. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast to other reports (3, 6, 7, 13), none of our patients presented with clinical signs and symptoms of adrenal insufficiency, and several of our patients (18) underwent only formal testing many years after presenting with DSD and/or skeletal malformations.”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Discussion
What the sources say
- Supportedcites [18] Idkowiak J O'Riordan S Reisch N Malunowicz EM Collins F Kerstens MN Kohler B Graul-Neumann LM Szarras-Czapnik M Dattani M Silink M Shackleton CHL Maiter D Krone N Arlt W 2011 Pubertal presentation in seven patients with congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 94: E453– E462 21190981 PMC3124345 source
The Discussion states that, despite neonatal presentation with DSD, the patients had not previously undergone adrenal-function assessment; adrenal insufficiency was diagnosed when they presented during puberty. The Results also report skeletal malformations noted at birth in five patients, without a conclusive diagnosis before puberty. Page numbers are not provided in our copy. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
57 more claims
Create a free account to see all 111 claims and to verify the 4 references still open.
- It may state two separate claims as one. 45
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Krone N et al. developed a scoring system to quantify the severity of skeletal anomalies based on their type and location, demonstrating that patients with mild to moderate deformities were typically compound heterozygotes for missense variants, whereas those with severe malformations often carried loss-of-function mutations such as frameshift or splice-site variants (21).”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While approximately half of all PORD patients require lifelong hydrocortisone replacement, others may only need supplemental doses during periods of physiologic stress (21, 28, 34).”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies consistently report that abnormal sexual development is generally more pronounced in female than in male patients with PORD (21, 42).”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mineralocorticoid production is preserved or enhanced, with hypertension typically manifesting in adulthood (16).”
From Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism (2019) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The severity of these malformations correlates with the underlying POR mutation.”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [21]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Spectrum of POR gene mutations
“the remaining 23 patients (21 unrelated) were compound heterozygous.”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Spectrum of POR gene mutations
“In two unrelated patients with classic clinical and biochemical PORD presentation, no POR mutation was detected either by direct sequencing or by MLPA analysis (Table 3).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Patients, Materials, and Methods > PORD malformation score
“| Maximum domain score | 3 | 3 | 3 | 3 | 2 | 2 |”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Malformation phenotype
“| 15 | A287P | IVS6 − 2A>T | P06 | 3 | 3 | 3 | 2 | 1 | 3 | Anteriorly placed anus, single umbilical artery, dysplastic ears |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Spectrum of POR gene mutations
“| 31,180 delC | p.Q455RfsX90 | Ex 11 | Frameshift | 1 | Novel |”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Spectrum of POR gene mutations
“| P10 | UK | Q455RfsX544 | IVS7 + 2dupT | NN | XY | Y | Y | n/a | 142 | 866 | − |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Genital phenotype
“patients of both sexes also presented with normal genital appearance consistent with their chromosomal sex (three females and six males), all of whom carried one major loss-of-function mutation.”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Genital phenotype
“Six patients were homozygous for p.A287P; all four 46,XX individuals presented with 46,XX DSD, whereas the two 46,XY individuals had normal male external genitalia.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Results > Genital phenotype
“three females and six males”
§ Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency > Abstract > Results:
“DSD was present in 15 of 18 46,XX and seven of 12 46,XY individuals.”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Arlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Self-citationMutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K., & Miller, W. L. (2004) · Nature Genetics · doi:10.1038/ng1300 · Cited by 509
Self-citationKrone, N., Hughes, B. A., Lavery, G. G., Stewart, P. M., Arlt, W., & Shackleton, C. H. L. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.04.010 · Cited by 434
Self-citationArlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., Chalder, S. M., Borucka-Mankiewicz, M., Hauffa, B. P., Malunowicz, E. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16503-3 · Cited by 345
Self-citationHuang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
Genetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
Self-citationLaboratory Guide to the Methods in Biochemical Genetics
(2008) · Springer eBooks · doi:10.1007/978-3-540-76698-8 · Cited by 244
Shen, A. L., O'Leary, K. A., & Kasper, C. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111408200 · Cited by 225
Huang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
Cited by
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationGenetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
Self-citationA Genetic-Pathophysiological Framework for Craniosynostosis
Twigg, S. R. F., & Wilkie, A. O. M. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.07.006 · Cited by 276
“A genotype-phenotype correlation is apparent, such that individuals with skeletal malformations are usually compound heterozygous for variants encoding a combination of a missense and a null allele; moreover, no subjects harboring homozygous null mutations have been encountered, supporting the conclusion from mouse st…”
BackgroundNADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Metadata
- Authors
- Krone, N., Reisch, N., Idkowiak, J., Dhir, V., Ivison, H. E., Hughes, B. A., Rose, I. T., O'Neil, D. M., Vijzelaar, R., Smith, M. J., MacDonald, F., Cole, T. R., Adolphs, N., Barton, J. S., Blair, E. M., Braddock, S. R., Collins, F., Cragun, D. L., Dattani, M. T., Day, R., Dougan, S., Feist, M., Gottschalk, M. E., Gregory, J. W., Haim, M., Harrison, R., Haskins Olney, A., Hauffa, B. P., Hindmarsh, P. C., Hopkin, R. J., Jira, P. E., Kempers, M., Kerstens, M. N., Khalifa, M. M., Köhler, B., Maiter, D., Nielsen, S., O'Riordan, S. M., Roth, C. L., Shane, K. P., Silink, M., Stikkelbroeck, N. M. M. L., Sweeney, E., Szarras-Czapnik, M., Waterson, J. R., Williamson, L., Hartmann, M. F., Taylor, N. F., Wudy, S. A., Malunowicz, E. M., Shackleton, C. H. L., & Arlt, W.
- Affiliations
- University of Birmingham (GB)
- MRC Holland (Netherlands) (NL)
- Birmingham Women's Hospital (GB)
- Royal Gwent Hospital (GB)
- National Health Service (GB)
- Saint Louis University (US)
- Cincinnati Children's Hospital Medical Center (US)
- University College London (GB)
- Kingston General Hospital (CA)
- Altonaer Kinderkrankenhaus (DE)
- University of California San Diego (US)
- Cardiff University (GB)
- Medical University of Graz (AT)
- Nottingham University Hospitals NHS Trust (GB)
- Essen University Hospital (DE)
- Jeroen Bosch Ziekenhuis (NL)
- University Medical Center Groningen (NL)
- Akron Children's Hospital (US)
- Charité – Universitätsmedizin Berlin (DE)
- Cliniques Universitaires Saint-Luc (BE)
- University of Nebraska Medical Center (US)
- University of Washington (US)
- Children's Hospital at Westmead (AU)
- Radboud University Medical Center (NL)
- University of Oklahoma Medical Center (US)
- Justus-Liebig-Universität Gießen (DE)
- University of London (GB)
- Corresponding author
- Arlt, Wiebke
- ORCID
- Krone, Nils
- Reisch, Nicole
- Idkowiak, Jan
- Dhir, Vivek
- Vijzelaar, Raymon
- MacDonald, Fiona
- Braddock, Stephen R.
- Cragun, Deborah L.
- Dattani, Mehul T.
- Dougan, Shelley
- Gottschalk, Michael E.
- Harrison, Rachel
- Hindmarsh, Peter C.
- Hopkin, Robert J.
- Kempers, Marlies
- Maiter, Dominique
- Roth, Christian L.
- Wudy, Stefan A.
- Arlt, Wiebke
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- E257-E267
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3380101
- OpenAlex
- W2158549435
- Cited by
- 163
- References
- 37
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 27 · 2023: 11 · 2022: 8 · 2021: 13 · 2020: 11 · 2019: 12 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 8 · 2014: 10 · 2013: 9 · 2012: 5
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Wellcome Trust (0900567, GR079865MA)
- Medical Research Council (0900567)
- FP7 Coordination of Non-Community Research Programmes (201444)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- P450 oxidoreductase deficiency, congenital adrenal hyperplasia, genotype-phenotype correlation, adrenal insufficiency, ACTH stimulation test, skeletal deformities, 17-hydroxylase deficiency, 21-hydroxylase deficiency, compound heterozygosity, loss-of-function mutations, Caucasian patients
- MeSH terms
- Adolescent, Adrenal Insufficiency, Adrenal Hyperplasia, Congenital, Adult, Child, DNA Mutational Analysis, Female, Genitalia, Humans, Male, Models, Biological, Models, Molecular, NADPH-Ferrihemoprotein Reductase, Disorders of Sex Development, Gonadal Steroid Hormones, Cohort Studies, Metabolome, Young Adult, Genetic Association Studies, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency. https://app.cochat.ai/papers/10.1210/jc.2011-0640
- The paper
- Krone, N., Reisch, N., Idkowiak, J., Dhir, V., Ivison, H. E., Hughes, B. A., Rose, I. T., O'Neil, D. M., Vijzelaar, R., Smith, M. J., MacDonald, F., Cole, T. R., Adolphs, N., Barton, J. S., Blair, E. M., Braddock, S. R., Collins, F., Cragun, D. L., Dattani, M. T., . . . Arlt, W. (2012). Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-0640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.